Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
ReviewHumansOther animals
- Design
- Review
- Subjects
- Not applicable; a narrative review
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Why palmitoylethanolamide might help white matter defects: its history, pharmacology and mechanisms, and evidence on white matter lesions and oligodendrocyte differentiation.
What the authors reported
The authors summarise PEA's analgesic, neuroprotective, immune-modulating and anti-inflammatory actions and recent findings that PEA-containing formulations promote oligodendrocyte differentiation, the first step in myelin formation. They discuss its potential for white matter defects in neurodegenerative disorders. No numbers are given.
Limits of this study
A narrative review, not new data; the cited oligodendrocyte findings are largely from cell and animal work. The authors declare no conflict of interest.
Source
PubMed 36139030 · doi:10.3390/biom12091191
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.